Zhitong Finance App News, China Biopharmaceutical (01177) announced that the Group's Class 1 innovative drugs “anlotinib (small molecule multi-target receptor tyrosine kinase inhibitor)”, “abergastine α (third-generation long-acting G-CSF)”, “piamprizumab (anti-PD-1)” and “FS222 (PD-L1/CD137 double antibody)”, “bemosubimab (anti-PDL1)”, “TQB3617 (BET inhibitor)”, “TQB3728” IAP antagonists), “TQB2930 ( “HER2 double antibody)” and others will announce 52 new research results at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, covering clinical research and basic research on various tumors such as bone and soft tissue sarcoma, lung cancer, head and neck tumors, digestive system tumors, gynecological tumors, breast cancer, and malignant tumors.
中国生物制药(01177)：52项研究成果将在2024年ASCO年会公布
China Biopharmaceutical (01177): 52 research results will be announced at the 2024 ASCO Annual Meeting
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.